RNAnalytics

Executive Summary

RNAnalytics is an Austrian biotech company founded in 2017 that provides standardized nanoparticle analytics for the RNA/LNP drug development sector. The company combines validated physical toolkits (RNABOX) with a cloud-native software platform (RNAOS) to improve data reproducibility and regulatory compliance, targeting CDMOs and biotech firms scaling CMC activities. As the demand for RNA therapeutics grows, RNAnalytics is well-positioned to become a key enabler for reliable nanoparticle characterization, accelerating development timelines and reducing variability in analytical methods. The integrated solution addresses a critical industry bottleneck: the lack of standardized analytics leading to inconsistent data. By offering both hardware and software, RNAnalytics streamlines the path from R&D to commercial manufacturing. With a focus on CDMOs and a presence in Vienna’s biotech hub, the company is poised to capture market share as more RNA therapies advance. Its unique value proposition in quality control and regulatory compliance positions it for growth in the expanding RNA/LNP ecosystem.

Upcoming Catalysts (preview)

• Q3 2026Strategic partnership with a major CDMO for platform adoption60% success
• Q2 2026Launch of next-generation RNABOX with enhanced throughput80% success
• Q4 2026Achievement of ISO 13485 certification for medical device compliance70% success